Journal article
Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability
ZD Cooper, G Bedi, D Ramesh, R Balter, SD Comer, M Haney
Neuropsychopharmacology | SPRINGERNATURE | Published : 2018
Abstract
Cannabinoids combined with opioids produce synergistic antinociceptive effects, decreasing the lowest effective antinociceptive opioid dose (i.e., opioid-sparing effects) in laboratory animals. Although pain patients report greater analgesia when cannabis is used with opioids, no placebo-controlled studies have assessed the direct effects of opioids combined with cannabis in humans or the impact of the combination on abuse liability. This double-blind, placebo-controlled, within-subject study determined if cannabis enhances the analgesic effects of low dose oxycodone using a validated experimental model of pain and its effects on abuse liability. Healthy cannabis smokers (N = 18) were admini..
View full abstractGrants
Awarded by National Institute on Drug Abuse
Funding Acknowledgements
This research was supported by US National Institute on Drug Abuse Grant DA19239, DA009236, and DA027755. ZDC, GB, DR, RB, SDC, and MH have no competing interests in relation to the work described. ZDC and MH have received research funds and partial salary support from Insys Therapuetics. Over the past 3 years, SDC received compensation (in the form of partial salary support) from studies supported by Braeburn Pharmaceuticals, Cerecor, Indivior, MediciNova, and Reckitt-Benckiser Pharmaceuticals. In addition, SDC has served as a consultant to the following companies over the past 3 years: Advances in Pain Management, AstraZeneca, Clinilabs, Collegium Pharmaceutical, Daiichi Sankyo, Depomed, Egalet, Endo, Guide point Global, Heptares Therapeutics Limited, Inspirion Delivery Sciences, IntelliPharma-Ceutics, Janssen, KemPharm, Mallinckrodt, Neuromed, Opiant, Orexo, Pfizer, and Shire.